Dizal (688192.SS) has released data from its pivotal phase 3 WU-KONG28 clinical trial, confirming that ZEGFROVY monotherapy significantly outperforms platinum-doublet chemotherapy in treating patients with untreated non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
The study, conducted entirely by Dizal’s oncology research team, marks a landmark advancement for patients with this historically challenging genetic subset of NSCLC. CEO Xiaolin Zhang emphasized the therapy’s transformative potential, stating, “WU-KONG28 establishes ZEGFROVY as the first effective first-line treatment for EGFR exon 20 insertion-mutated NSCLC, offering a chemotherapy-free alternative with improved survival outcomes for patients worldwide.”
This breakthrough follows ZEGFROVY’s accelerated approvals in the U.S. and China for treating relapsed or refractory cases of EGFR ex20 ins NSCLC. Dizal has concurrently submitted a New Drug Application (NDA) for its use in first-line therapy, with China’s National Medical Products Administration granting Priority Review designation to accelerate regulatory processes.
Check out the latest updates on ZEGFROVY’s clinical milestones via @DizalPharma’s official account.
For more insights into cancer treatment advancements, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.